SynthesisAdvances in rheumatology (London, England)2020
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Synthesis in Advances in rheumatology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.Advances in rheumatology (London, England) · 2024Guideline
- Efficacy and safety of hydroxychloroquine in osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.The Korean journal of internal medicine · 2022Pooled it
- Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.Nature communications · 2021Pooled it
- Osteoarthritis and rheumatoid arthritis: A comparative review of pathophysiology, diagnosis and evolving management.Journal of Taibah University Medical Sciences · 2026Review
- The Combination of Thymoquinone and Chloroquine Dose-Dependently Regulates Autophagy and Potentiates Metastatic Melanoma Cell Death via Autophagy-Dependent and -Independent Mechanisms.International journal of molecular sciences · 2026Article
- Contrast Sensitivity and Colour Vision Tests for Early Detection and Monitoring of Hydroxychloroquine Retinal Toxicity: A Preliminary Study.Journal of clinical medicine · 2026Article
- Review
- Hydroxychloroquine Retinopathy in Systemic Lupus Erythematosus: Risk Factors, Screening, and Emerging Biomarkers.Journal of ophthalmology · 2026Review
- The effect of Hippophae rhamnoides on Hydroxychloroquine-Induced stomatitis in rats.BMC complementary medicine and therapies · 2025Article
- The Role of Hydroxychloroquine in the Management of Rheumatic Disorders: A Comprehensive Review.Basic & clinical pharmacology & toxicology · 2025Review
- Predicting rare drug-drug interaction events with dual-granular structure-adaptive and pair variational representation.Nature communications · 2025Article
- Article
- Hydroxychloroquine: A double‑edged sword (Review).Molecular medicine reports · 2025Review
- Systemic lupus erythematosus: pathogenesis and targeted therapy.Molecular biomedicine · 2024Review
- Hydroxychloroquine as an Adjunct Therapy for Diabetes in Pregnancy.International journal of molecular sciences · 2024Review
- Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS).Lupus science & medicine · 2024Article
- The effect of hydroxychloroquine on cholesterol synthesis depends on the profile of cholesterol metabolism. A controlled clinical study.Atherosclerosis plus · 2024Article
- Review
- The effect of hydroxychloroquine on cholesterol metabolism in statin treated patients after myocardial infarction.Atherosclerosis plus · 2023Article
- Long COVID in autoimmune rheumatic diseases.Rheumatology international · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.